结肠透析治疗对慢性肾衰竭患者微炎症及营养状态的影响

目的：观察结肠透析治疗对慢性肾衰竭（CRF）患者微炎症及营养状态的影响。方法：将80例CRF患者随机分成治疗组和对照组各40例,两组患者在常规治疗的基础上,治疗组给予结肠透析治疗,对照组给予口服尿毒清颗粒治疗,疗程均为1个月,观察两组患者治疗前后肾功能、微炎症及营养指标的变化。结果：治疗组治疗后血肌酐（Scr）、尿素氮（BUN）、超敏C-反应蛋白（hsCRP）水平均有明显下降且优于对照组（P〈0.05或P〈0.01）,前白蛋白（PAB）水平较治疗前明显升高且优于对照组（P〈0.05）。结论：结肠透析治疗可改善CRF患者的微炎症及营养状态,延缓肾功能进展,延长非透析治疗时间,是一种安全、有效且容易被患者接受的治疗方法,适用于CRF早中期特别是合并有习惯性便秘的患者。     

活血复肾胶囊对慢性肾衰竭大鼠微炎症状态的影响

目的探讨活血复肾胶囊对慢性肾衰竭过程中微炎症状态的影响。方法采用腺嘌呤制作大鼠慢性肾衰竭模型,将大鼠分为3组：正常对照组（A组）10只、模型对照组（B组）10只、活血复肾胶囊治疗组（C组）10只,采用自身对照方法,观察3组大鼠治疗4周前后血肌酐,尿素氮,C-反应蛋白及肿瘤坏死因子的改变。结果B组存在肾功能损害,C-反应蛋白及肿瘤坏死因子明显增高。采用活血复肾胶囊治疗后C组与B组相比,C-反应蛋白及肿瘤坏死因子水平明显下降。结论在慢性肾衰竭大鼠模型中,存在微炎症状态;活血复肾胶囊可能具有调节慢性肾衰竭微炎症状态的作用。     

慢性肾衰竭营养不良患者微炎症状态与中医辨证分型的关系

目的：探讨慢性肾衰竭营养不良微炎症状态与中医辨证分型的关系。方法：300例慢性肾衰竭营养不良患者,包括非透析患者126例、血液透析患者114例、腹膜透析患者60例,按SGA评分方法分为轻、中、重度营养不良,根据慢性肾衰竭中医辨证分型标准进行辨证分型。另设健康对照组30例。测定血清白细胞介素-6（IL－6）、肿瘤坏死因子－α（TNF-α）、超敏C反应蛋白（hs—CRP）等指标,分析慢性肾衰竭营养不良微炎症指标与中医辨证分型之间的关系。结果：慢性肾衰竭营养不良患者hs—CRP、IL-6、TNF—α水平均明显高于健康对照组。肝肾阴虚证、阴阳两虚证亚组血清hs—CRP、IL-6、TNF—α水平较其他三组均明显增高（P〈0．01或P〈0．05）,湿热证及热毒证亚组血清hs—CRP、IL-6水平高于其他两组（P〈0．01或P〈0．05）,湿热证亚组TNF～α水平明显高于其他三组（P〈0．01或P〈0．05）。结论：慢性肾衰竭营养不良患者普遍存在微炎症状态,hs—CRP、IL-6、TNF—α在慢性肾衰竭营养不良患者与肝肾阴虚、阴阳两虚及湿热、热毒证密切相关。     

左卡尼汀对慢性肾衰竭大鼠心脏的保护作用

目的 观察左卡尼汀对慢性肾衰竭大鼠心脏病理变化的影响,并探讨其心脏保护机制.方法 55只雄性SD大鼠按数字随机法分为假手术组(n=10)、模型组(n=15)、左卡尼汀小剂量组(n=10)、中剂量组(n=10)和大剂量组(n=10).除假手术组外,其余各组大鼠行5/6肾切除术.造模后1周,各左卡尼汀组大鼠每日灌胃给药,剂量分别为300、600、900mg/kg.假手术组和模型组则每日予生理盐水灌胃,总疗程17周.观察大鼠24h尿蛋白量、肾功能、超氧化物歧化酶(SOD)、丙二醛( MDA)、白介素6(IL-6)、三磷酸腺苷(ATP)、二磷酸腺苷(ADP)变化.实验结束时,测各组大鼠平均动脉压及心率,并通过心脏超声、全心/体质量比、光镜、透射电镜观察大鼠心脏病理变化.结果 (1)左卡尼汀小、中、大剂量组ATP(μmol/g体质量)(2.35±0.24,3.59±0.28,3.78±0.25)均显著高于模型组(1.61±0.12)(均P＜0.01).(2)心脏超声显示左卡尼汀大剂量组左心室后壁厚度(mm)小于模型组(3.74±0.23比4.18±0.48,P＜ 0.05).(3)左卡尼汀中、大剂量组全心/体质量比值(3.92±0.27,3.65±0.20)均显著低于模型组(3.99±0.27)(P＜ 0.01).(4)光镜下,HE染色显示模型组心肌细胞排列紊乱,心肌细胞肥大;Masson染色显示胶原组织明显增多,部分心肌组织被胶原组织取代,出现心肌间质纤维化.HE染色显示左卡尼汀中、大剂量组心肌细胞排列紊乱;Masson染色显示心肌组织周围胶原纤维增多,心肌间质纤维化,但病变程度和范围均明显减轻.左卡尼汀中、大剂量组心肌病理评分(7.14±1.07,6.13±0.99)均低于模型组(9.88±1.13)(P＜ 0.01).电镜下,模型组可见大片心肌纤维溶解,线粒体增多、肿胀、空泡化,膜断裂、基质加深,为典型的心肌肥厚表现.左卡尼汀治疗组呈剂量依赖性改善病理损害.(5)治疗17周时,左卡尼汀小、中、大剂量组IL-6 (ng/L)(261.86±13.18、240.12±18.70、233.34±36.88比596.64±81.41)和MDA (nmol/L)(15.23±2.01、12.41±0.60、10.97±1.90比21.84±2.71)显著低于模型组;SOD(U/ml)(51.20±6.11、58.51±5.52、60.63±6.94比32.01±5.69)则高于模型组,差异均有统计学意义(均P＜ 0.05).(6)各组大鼠心率差异无统计学意义;模型组和左卡尼汀各组收缩压、舒张压及平均动脉压比较,差异无统计学意义.结论 左卡尼汀可通过改善慢性肾衰竭大鼠的心肌能量代谢、微炎性反应及氧化应激,达到延缓慢性肾衰竭大鼠左心室肥厚、心肌间质纤维化的作用.     

虫草肾茶方对慢性肾衰竭非透析患者微炎症状态的改善作用

慢性肾衰竭（chronic renal failure，CRF）是指发生在各种慢性肾脏疾病后期的一种临床综合征。近期研究表明，CRF不但是机体针对肾功能进行性衰竭所产生的一系列复杂的细胞、生化反应，而且还是一个以细胞因子驱动的、以促氧化过程为特征的全身性的慢性炎症状态。临床上往往没有明显症状，有学者称其为慢性肾衰竭的“微炎症反应”。本文通过虫草肾茶方的临床研究，     

慢性肾衰竭微炎症状态的研究进展

慢性肾衰竭（CRF）是常见的临床综合征，它是在各种慢性肾脏病的基础上，缓慢出现的肾功能逐渐减退，最终成为终末期肾脏疾病（ESRD），导致肾衰竭。近年研究表明，ESRD患者病死率明显高于一般人群，除了与患者存在高血压、高脂血症、糖尿病以及一些特殊因素，如血透间期容量超负荷、贫血、高同型半胱氨酸血症、高过氧化反应状态有关外，还与患者存在微炎症反应状态有密切的联系。     

三七总苷对慢性肾衰竭大鼠模型肾纤维化的治疗作用及机制

目的：研究三七总苷对5/6肾切除大鼠肾纤维化的防治作用。方法：SD大鼠60只,随机分为假手术组和手术组,手术组行5/6肾切除术。术后3周,假手术组随机分为假手术未治疗组和假手术三七总苷组,手术组随机分为手术模型组、三七总苷低、中、高剂量组。各组于术后4周分别给予生理盐水或相应剂量的三七总苷灌胃。治疗4周后处死大鼠,取残肾检测肾脏病理;应用免疫组化法检测肾组织α-SMA、TGF-β1的表达;应用RT-PCR法检测肾组织α-SMA mRNA、TGF-β1 mRNA的表达。结果：手术组与假手术组比较,病理损伤程度显著增加,肾组织α-SMA、TGF-β1表达显著升高,各治疗组有所回降。结论：三七总苷能显著改善肾小球硬化和肾小管-间质纤维化;三七总苷可能通过下调残肾组织内的TGF-β1表达,抑制肾脏固有细胞表型转化而起抗肾纤维化作用。     

慢性肾衰竭患者瘦素与心钠素的关系

心钠素 (ＡＮＰ) ,具有扩张血管、降低血压的同时诱发利尿利钠效应 ,也能直接抑制肾小球旁器、肾上腺激素及醛固酮的释放 ,增加肾小球的滤过率 ,并可影响中枢及交感神经活性和压力反射功能 ,ＡＮＰ的上述效应预示着ＡＮＰ对ＣＲＦ可能具有重要的治疗价值 ,但ＢｕｃｋａｌｅｗＶＭ等报道ＡＮＰ在ＣＲＦ患者中没有显示满意的疗效[1] ,提示还有其他因素参与。肾脏是瘦素和ＡＮＰ降解和清除的主要场所 ,ＣＲＦ时瘦素与ＡＮＰ在体内水平发生变化。本研究旨在探讨慢性肾衰竭患者瘦素与ＡＮＰ的关系。资料与方法1　一般资料　 (1)未透析组 :本院肾…     

降浊颗粒对慢性肾衰竭模型微炎症状态的影响

目的：采用5/6肾切除方法建立大鼠慢性肾衰竭动物模型。以中药复方制剂＂降浊颗粒＂进行治疗,观察并评价治疗效果,探讨降浊颗粒对慢性肾衰竭模型微炎症状态的影响。方法：将大鼠随机分为正常组、模型组、对照组和治疗组。治疗组、对照组手术4周后给予＂降浊颗粒＂3.35g.kg-1.d-1灌胃,对照组给予＂尿毒清＂300mg·kg-1.d-1灌胃,模型组同时给予等量生理盐水灌胃;疗程8周。分别于给药前、第8周检测肌酐、尿素氮、24h尿蛋白定量,于第8周检测血C-反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）水平。结果：治疗组大鼠一般情况优于对照组,治疗组给药前BUN、Scr、24h尿蛋白定量与对照组比较差异无统计学意义（P〉0.05）,第8周BUN、Scr、24h尿蛋白定量、CRP、TNF-α明显低于模型组（P〈0.01）,BUN、Scr、CRP、TNF-α的改变优于对照组（P〈0.05）。结论：＂降浊颗粒＂对慢性肾衰竭大鼠有较好的治疗效果,可延缓慢性肾衰竭进展。其机制可能与减轻慢性肾衰竭微炎症反应有关。     

慢性肾衰竭患者的肾脏病理分析

慢性肾衰竭(chronic renal insufficiency,CRI)是各种原因所致肾脏损伤后持续进展导致肾功能慢性减损的临床情况,是多种肾脏疾病持续进行性发展的最终阶段。如由IgA肾病引起的CRI患者血肌酐升高超过265μmol/L以后,若血肌酐水平在短时间内迅速上升,患者在平均10个月的时间内会进展为终末期肾病[1]。此类患者血肌酐一旦超过177μmol/L就很难     

心衰患者尿酸对血管内皮功能的影响及别嘌呤醇的干预

目的探讨心力衰竭（心衰）患者尿酸（UA）升高对血管内皮功能的影响及别嘌呤醇干预对尿酸升高的慢性心衰内皮依赖性血管舒张功能的影响。方法将30例心衰患者随机分为别嘌呤醇组和对照组，对照组15例，用常规药物治疗2周；别嘌呤醇组15例，在常规药物治疗基础上加用别嘌呤醇。采用高分辨超声技术检测血流介导和硝酸甘油介导的肱动脉舒张功能，并测定治疗前后血浆UA和内皮素（ET-1）。结果（1）用药前，二者比较UA水平及ET-1水平，差异无统计学意义（P〉0．05）；用药后，别嘌呤醇组UA水平及ET-1水平和对照组比较均降低，差异有统计学意义（P〈0．05）。各组用药后UA水平及ET-1水平均明显降低（P〈0．01）。（2）别嘌呤醇组和对照组肱动脉内径基础值无明显差异（P〉0．05），反应性充血引起肱动脉内径变化别嘌呤醇组明显增加（P〈0．01）。含服硝酸甘油后两组肱动脉内径均明显扩张，但两组肱动脉内径变化无明显差异（P〉0．05）。结论心衰患者经药物干预后，UA水平降低，ET-1水平随之下降，尤以别嘌呤醇组降低明显。别嘌呤醇治疗后UA水平明显降低，内皮依赖性血管舒张功能明显改善，别嘌呤醇是慢性心衰的一种便宜而有效的辅助药物。     

非布司他与别嘌醇治疗慢性肾脏病合并高尿酸血症的疗效比较

目的探讨非布司他与别嘌醇在治疗慢性肾脏患者合并高尿酸血症的临床疗效分析比较。方法回顾性分析2013年1月至2015年2月中国人民解放军第174医院收治的78例慢性肾脏病合并高尿酸血症患者,并根据治疗方法将其分为对照组和治疗组。2组患者均采用优质低蛋白饮食、降压[钙通道阻滞剂和(或)β受体阻滞剂]、纠正贫血(促红细胞生长素)、补充α酮酸(开同)及纠正水、电解质酸碱平衡(碳酸氢钠)等综合治疗;观察组加用非布司他20 mg/d,对照组加用别嘌醇100 mg/d;2组均治疗观察24周。分析治疗前后2组患者血肌酐、血尿酸及临床疗效,并进行统计学分析。结果 2组治疗前后实验室相关指标比较结果表明2组治疗后血尿酸与治疗前比较,均有显著改善(均P0.05),且治疗组患者治疗后尿酸与对照组行组间比较有统计学差异(P0.05)。治疗组治疗后血肌酐与治疗前比较明显降低,有统计学差异(P0.05);而对照组治疗前后血肌酐无明显变化(P0.05)。治疗组临床总有效率高于对照组(P0.05)。2组均未发现明显的不良反应。结论非布司他相对于别嘌醇降低血尿酸水平的作用更强,且可改善肾功能,药物不良反应较小,因此在治疗慢性肾脏合并高尿酸血症患者上具有良好的应用前景。     

慢性肾功能衰竭患者的高同型半胱氨酸血症

目的 研究慢性肾功能衰竭（ＣＲＦ）患者血浆同型半胱氨酸（Ｈｃｙ）水平、影响因素以及与心、脑血管疾病的关系。方法 采用荧光偏振免疫分析法测定１６０例ＣＲＦ患者血浆总同型半胱氨酸（ｔＨｃｙ）水平，以３１例冠心病患者和４５例正常人为对照。结果 以正常组血浆ｔＨｃｙｘ±２ｓ为９５％可信度上限，ＣＲＦ患者高同型半胱氨酸血症的发生率为８２．５０％，明显高于冠心病组（２２．５８％）（Ｐ＜０．０１）；血液透析（ＨＤ）组血浆ｔＨｅｙ水平［（２４．１３±１２．６８）μｍｏｌ／Ｌ，ｎ＝７３］明显高于持续性非卧床腹膜透析（ＣＡＰＤ）组［（１６．４３ ±５．５８）μｍｏｌ／Ｌ，ｎ＝１９］、冠心病组［（１１．１３±４．９７）μｍｏｌ／Ｌ，ｎ＝３１］以及正常组（７．９７±２．６５）μｍｏｌ／Ｌ，ｎ＝４５，Ｐ均＜０．０１。９２例透析治疗的ＣＲＦ患者中有明确心、脑血管病者的血浆ｔＨｃｙ水平［（２７．１２±１５．９４）μｍｏｌ／Ｌ，ｎ＝３０］明显高于无此类病史的患者［（２０．１７±８．７１）μｍｏｌ／Ｌ，ｎ＝６２］。未经透析的 ＣＲＦ患者血浆 ｔＨｃｙ水平与内生肌酐清除率呈负相关（ｒ＝－０．３７４，Ｐ＜０．０１），与患者年龄、血葡萄糖、血脂及血浆白     

慢性肾衰竭患者继发甲状旁腺功能亢进外科治疗进展

随着透析技术的进步,慢性肾衰竭患者的生存时间逐渐延长,但影响患者生活质量甚至严重威胁患者生命的许多并发症也随之出现.继发性甲状旁腺功能亢进(SHPT)是血液透析患者的常见并发症之一,并且有一定的发病率和病死率,特征性表现主要有:低钙、高磷和高甲状旁腺激素.大多数患者可以通过药物治疗而痊愈,然而,药物治疗并不是都能很好地调节甲状旁腺功能的紊乱,部分患者需要外科干预.本文对慢性肾衰竭血透患者SHPT外科治疗的现状做一综述.

Abstract：

With the development of the dialysis technology,the survival time of patients with chronic renal failure is prolonged,while more complications which affect the quality of life or even threat the life of patients are followed.Secondary hyperparathyroidism(SHPT)with a certain incidence and mortality is one of the common complications,and its main characteristic performances ale hyperphosphatemia,hypocalcemia and high level of parathyroid hormone.Most patients Can be cured by the treatment of medicine while surgical treatment is still required by some cases in which the disorder of the parathyroid function can not be well regulated through medicine treatment.The purpose of this paper is to make a review of the recent studies of surgical treatment in patients with SHPT.     

The urate-lowering efficacy of febuxostat and its effect on renal function in hyperuricemic patients with chronic kidney disease stages 3-5

Objective To investigate the urate-lowering efficacy and renal effect of febuxostat in hyperuricemic patients with chronic kidney disease (CKD) stages 3-5. Methods A prospective, randomized, controlled trial of CKD stages 3-5 patients with hyperuricemia was conducted from June 2015 to June 2016. Patients were randomly assigned to either febuxostat group (treatment group) or allopurinol group (control group). Patients in treatment group received febuxostat 40 mg/d after study initiation, and the dosage was changed to 20 mg/d if serum uric acid (sUA)＜360 μmol/L. Patients in control group were administered a dose of 100 mg/d of allopurinol. Serum uric acid, serum creatinine and other clinical parameters were measured at baseline and 1-6 months after treatment. The rate of achieving target sUA level and the change of eGFR in two groups were performed using SPSS 21.0. Results A total of 98 patients met the inclusion criteria and completed the trial. The treatment group and the control group had 51 cases and 47 cases, respectively. There was no significant difference between the two groups in age, sex, body mass index (BMI), blood pressure, serum creatinine, eGFR, sUA and renal diseases (P＞0.05). At month 1-6, there were significant differences between treatment group and control group in the rate of achieving target sUA level (P＜0.01). At month 1 and month 3, no statistical difference was observed in the change of eGFR between the two groups (P=0.624, P=0.319). At month 6, the changes in eGFR were +2.23 ml?min-1?(1.73 m2)-1 and -4.36 ml?min-1?(1.73 m2)-1 in the treatment and control group, respectively, and the difference between the two groups was significant (P=0.037). In patients with CKD stages 3-5, generalized estimating equation showed that after adjusting for confounding variables, the eGFR increased 1.149 ml?min-1?(1.73 m2)-1 (P=0.003) and 24-hour urinary protein decreased 0.019 g/d (P=0.037) when per 60 μmol/L decreased in sUA. Febuxostat 20 mg/d was able to keep target sUA levels in 90.2% patients with CKD stages 3-5 within half a year and no serious adverse effects appeared. Conclusions Febuxostat performs better than allopurinol in lowering urate and delaying progression of renal function in patients with CKD stages 3-5 and HUA. Febuxostat 20 mg/d may be the effective and safe maintenance dose to maintain target sUA level in patients with CKD stages 3-5, but whether it can be used as the best long-term maintenance dose needs to be further studied.     

温肾降浊胶囊治疗慢性肾衰竭的临床研究

目的:探讨温肾降浊胶囊治疗慢性肾衰竭(CRF)的临床疗效和作用机制。方法:75例CRF患者随机分为治疗组40例、对照组35例,两组患者均用低蛋白饮食、纠正代谢性酸中毒及电解质紊乱常规治疗。对照组予以包醛氧淀粉治疗,治疗组予以温肾降浊胶囊治疗。共治疗3月,检测两组患者治疗前后血肌酐(Scr)、尿素氮(BUN)、血红蛋白(Hb)的变化情况。结果:治疗组治疗后,Scr、BUN明显下降、Hb升高显著。与对照组治疗后比较Scr、BUN下降(P<0.05),Hb升高(P<0.05),有显著性差异。结论:①温肾降浊胶囊对CRF早中期的治疗作用肯定;②通过降低Scr、BUN纠正贫血而发挥其良好的治疗作用;③温肾降浊胶囊治疗CRF优于包醛氧淀粉,临床上值得推广。     

慢性肾衰大鼠细胞免疫功能的初步研究

采用慢性肾衰大鼠模型，观察其细胞免疫功能的变化，结果显示：慢性肾衰组大鼠的胸腺绝对重量和相对重量均明显低于正常对照组和模拟手术组，慢性肾衰组大鼠的Ｔ淋巴细胞转化功能亦显著低于正常对照组和模拟手术组，提示尿毒症本身可导致Ｔ淋巴细胞数量减少和功能低下，慢性肾衰患者应加强合理的免疫调节治疗。     

长期血液透析患者内皮祖细胞变化与同型半胱氨酸的关系

目的检测长期血液透析患者内皮祖细胞（EPCs）数量和功能的改变,并探讨其与同型半胱氨酸的关系。方法采用密度梯度离心法分离培养长期血液透析患者和健康者的外周血单个核细胞,将其接种在人纤维连接蛋白包被培养板,7d后取贴壁细胞进行Dil—LDL和FITC—UEA-I双染色,并通过流式细胞仪检测其表面标志CD34、CD133、KDR,以鉴定EPCs。采用改良的Boyden小室、粘附功能检测评价其迁移和粘附能力,并与患者血清半胱氨酸含量进行相关性分析。结果患者EPCs的数量和迁移、粘附功能都低于健康者,差异有统计学意义（P〈0．05）;患者血清半胱氨酸含量[（57．10±24．76）umol／L]显著高于健康者[（6．75±3．58）umol／L]（P〈0．05）,并且含量与患者EPCs的数量和迁移、粘附功能分别呈明显负相关（P〈0．05）。结论长期血液透析患者的EPCs数量减少,功能降低,可能与患者的高同型半胱氨酸血症有关。     

Changes in intestinal flora and its correlation with renal function in chronic renal failure patients

Objective To investigate changes in intestinal bacteria in chronic renal failure (CRF), their diagnostic value for CRF, and correlations between specific bacterial genera and renal function. Methods Fecal specimens were collected from 56 patients with CRF and 38 healthy controls in the Nephrology Department and Medical Examination Center of Shanxi People's Hospital between August 2017 and January 2018. High-throughput sequencing analysis of 16S rDNA V3-V4 hypervariable regions was performed for intestinal bacteria. Intestinal bacteria in CRF patients and healthy subjects were analyzed for alpha, beta diversity, species composition analysis, and differential species analysis. The diagnostic value of the presence of specific intestinal bacteria for CRF was analyzed using a receiver operating characteristic curve (ROC). Pearson's correlation analysis was used to analyze the correlation between the presence of specific genera and the estimated glomerular filtration rate (eGFR). Results The alpha and beta diversity in the CRF group was different from that in the control group (P﹤0.05). At the phylum level, Verrucomicrobia were significantly less abundant in the CRF group than that in the control group (0.70% vs 3.09%, P﹤0.001). The abundance of Actinobacteria was significantly greater in the CRF group than that in the control group (1.48% vs 1.14%, P=0.036). At the genus level, the abundance of Akkermansia (0.96% vs 3.90%), Parasutterella (0.47% vs 0.93%), and Lactobacillus (0.07% vs 0.48%) in the CRF group was significantly less than those in the control group (all P﹤0.01). The abundance of Alloprevotella (0.41% vs 0.04%) and Clostridium IV (0.6% vs 0.1%) was significantly greater than those in the control group (all P﹤0.05). The diagnostic value of CRF for the area under the ROC curve (AUC) for Akkermansia was 0.753, and that for Lactobacillus diagnostic value of CRF was 0.792. The combined AUC diagnostic value of CRF for detection of Akkermansia and Lactobacillus was 0.830, with high disease prediction value. Lactobacillus abundance was positively correlated with eGFR (R=0.29, P=0.029). Conclusions The diversity and structure of intestinal bacteria are altered in patients with CRF. The abundance of Akkermansia and Lactobacillus has diagnostic value for CRF. The abundance of Lactobacillus is positively correlated with eGFR.     

Significant benefits after renal transplantation in patients with chronic heart failure and chronic kidney disease

Background: Chronic heart failure (CHF) and chronic kidney disease (CKD) are serious medical conditions with significant morbidity and mortality and often coexist. Because of perioperative risks in these patients, they may not be considered a candidate for renal transplantation (RTx).

Material and methods: We compare retrospectively RTx outcomes [graft/patient survival, rejection rates and adverse cardiac events] in study group [low left ventricular ejection fraction (LVEF) ≤45% by echocardiogram, n?=?63] and control group [normal LVEF ≥50%, n?=?537] from a developing country.

Results: The mean EF was 35?±?5.6 and 57?±?3% for the study and control groups, respectively (p?Conclusion: RTx may play a role in reversing LV systolic dysfunction. Once thought by many to be a contraindication for renal transplantation, this appears not to be the case. The outcomes between the 2 groups are comparable and transplant is an option for even low EF patients.